Search clinical trials for: Reference Empagliflozin And Linagliptin tablets

Total 7650 results

Medical University of Vienna

Recruiting

Trial to Investigate the Effect of Dapagliflozin on Ischemia Reperfusion Induced Endothelial Dysfunction

Reperfusion Injury | Vascular Complications

Austria
George Medicines PTY Limited
The George Institute; Brandon Biocatalyst

Not yet recruiting

Polypill Versus Metformin in New Onset Type 2 Diabetes (PiVOT)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
CHEOL WHAN LEE, M.D., Ph.D

Completed

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease (ELITE)

Coronary Disease | Diabetes Mellitus

Korea, Republic of
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
Boehringer Ingelheim

Completed

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

Diabetes Mellitus, Type 2

Germany
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

Healthy

United States
LG Chem

Unknown

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Type 2 Diabetes Mellitus

Korea, Republic of
Fayoum University
Boehringer Ingelheim

Completed

Contrast Nephropathy in Type 2 Diabetes (VCG4)

Diabetes | Microalbuminuria | Kidney Function Affection Upon Exposure to Radiocontrast

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

Diabetes Mellitus, Type 2

United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
University of Oxford
Oxford Brookes University; The Leona M. and Harry B. Helmsley Charitable Trust

Terminated

Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia (DEPTH)

Diabetes Mellitus, Type 1

United Kingdom
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
Boehringer Ingelheim
Eli Lilly and Company

Completed

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, France, Israel, Mexico, South Africa
AstraZeneca

Completed

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Type 2 Diabetes Mellitus

Japan
SINA Health Education and Welfare Trust

Completed

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Polycystic Ovary Syndrome | Weight Gain | HbA1c

Pakistan
Asmaa Abdelfattah Elsayed

Completed

Follow-up of NAFLD Patients With MRI-PDFF

NAFLD | Diabetes Type 2

Egypt
Medanta, The Medicity, India

Recruiting

Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (Dapa-LiT)

Diabetes Mellitus | Liver Transplant; Complications

India
University Health Network, Toronto
Sunnybrook Health Sciences Centre; MOUNT SINAI HOSPITAL

Recruiting

DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)

Cardiovascular Risk Factor

Canada
University of California, San Diego
Juvenile Diabetes Research Foundation

Completed

Dapagliflozin Effects on Hypoglycemia

Type1 Diabetes Mellitus

United States
Pfizer

Completed

Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States

Bioequivalence

China
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy (ESPRIT)

Ischemic Stroke, Acute

China
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
AIDS Arms Inc.

Completed

A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort

HIV-1 | AIDS

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Apixaban Tablets in Healthy Chinese Subjects

Healthy

China
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Samsung Medical Center

Recruiting

SGLT2 Inhibitor for Severe Tricuspid Regurgitation (Reduction-TR)

Tricuspid Regurgitation

Korea, Republic of
Damanhour University
Menoufia University

Unknown

Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial

Cardiomyopathies | Diabete Type 2 | Heart Failure With Reduced Ejection Fraction (HFrEF)
Boehringer Ingelheim

Completed

Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers

Healthy
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
Assistance Publique - Hôpitaux de Paris

Recruiting

Do Patients Want to Engage in Discussions Dedicated to Anticipating (DDA) Their Preferences of Care in the Event of Worsening Health Status? (ESOP)

Neoplasm Metastasis | Advanced Cancer | Locoregional Neoplasm

France
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers

Neoplasms

China
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Therapeutic Equivalency

China
University of Virginia

Recruiting

Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery Disease (SMILE)

Myocardial Ischemia

United States
Boehringer Ingelheim
Eli Lilly and Company

Withdrawn

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Completed

Linagliptin in Post-renal Transplantation

Transplanted Kidney Complication
Boehringer Ingelheim

Completed

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Austria, Czech Republic, Estonia, Finland, France, Germany, Hungary, Latvia, Norway, Romania, Russian Federation, Slovakia, Spain, Ukraine
University Hospital, Basel, Switzerland

Completed

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study (DIVE)

Inappropriate ADH Syndrome

Switzerland
Léman Micro Devices SA

Withdrawn

A Study to Demonstrate the Clinical Accuracy of the Smartphone Vital Signs System (SVSS)

Healthy Volunteers

Switzerland
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
JW Pharmaceutical

Completed

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone (CWP-DIANA-302)

Type 2 Diabetes Mellitus

Korea, Republic of
Laboratorios Andromaco S.A.

Completed

Bioavailability of Eszopiclone 3.0 mg With Regards to Reference Product

Bioequivalence

India
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Tan Tock Seng Hospital

Recruiting

Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes (DMVascular)

Diabetes

Singapore
IPCA Laboratories Ltd.

Completed

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition

Fasting

India
Boehringer Ingelheim

Completed

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

Healthy
JW Pharmaceutical

Completed

To Evaluate the Safety and PK Characteristics in Healthy Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Belgium, Canada, China, France, Germany, Greece, India, Ireland, Japan, Korea, Republic of, Mexico, Philippines, Slovakia, Slovenia, Switzerland, Taiwan, Turkey, Ukraine

3

Subscribe